Resource Summary Report

Generated by PRECISE-TBI on Aug 10, 2026

Brilliant Violet 650(TM) anti-human IL-2

RRID:AB_2563878
Type: Antibody

Proper Citation

BioLegend Cat# 500334, RRID:AB_2563878

Antibody Information

URL: http://antibodyregistry.org/AB_2563878

Proper Citation: BioLegend Cat# 500334, RRID:AB_2563878

Target Antigen: IL-2

Host Organism: rat

Clonality: monoclonal

Comments: Applications: ICFC

Antibody Name: Brilliant Violet 650(TM) anti-human IL-2

Description: This monoclonal targets IL-2

Target Organism: human

Clone ID: Clone MQ1-17H12

Antibody ID: AB_2563878

Vendor: BioLegend

Catalog Number: 500334

Alternative Catalog Numbers: 500333

Record Creation Time: 20250819T232628+0000

Record Last Update: 20250820T052055+0000

Ratings and Alerts

No rating or validation information has been found for Brilliant Violet 650(TM) anti-human IL-2.

No alerts have been found for Brilliant Violet 650(TM) anti-human IL-2.

Data and Source Information

Source: Antibody Registry

Usage and Citation Metrics

We found 7 mentions in open access literature.

Listed below are recent publications. The full list is available at PRECISE-TBI .

Lee YJ, et al. (2025) Tumor-specific but immunosuppressive CD39+CD8+ T cells exhibit double-faceted roles in clear cell renal cell carcinoma. Cell reports. Medicine, 102360.

Saggau C, et al. (2024) Autoantigen-specific CD4+ T cells acquire an exhausted phenotype and persist in human antigen-specific autoimmune diseases. Immunity, 57(10), 2416.

Hartana CA, et al. (2023) IL-15-dependent immune crosstalk between natural killer cells and dendritic cells in HIV-1 elite controllers. Cell reports, 42(12), 113530.

Krämer B, et al. (2023) Single-cell RNA sequencing identifies a population of human liver-type ILC1s. Cell reports, 42(1), 111937.

Daumoine S, et al. (2023) Protocol for simultaneous analysis of peripheral and intratumoral lymphocyte function by flow cytometry. STAR protocols, 4(4), 102658.

Ortiz AM, et al. (2023) Experimental bacterial dysbiosis with consequent immune alterations increase intrarectal SIV acquisition susceptibility. Cell reports, 42(1), 112020.

Hoang TN, et al. (2021) Baricitinib treatment resolves lower-airway macrophage inflammation and neutrophil recruitment in SARS-CoV-2-infected rhesus macaques. Cell, 184(2), 460.